afternoon, good everyone. Jackie, and Thank you,
expectations. ago, second fell reported quarter of weeks we our few which A revenue, short
result. I this actions the disappointed the to very are shortfall to of a and you taking with like components walk next as we're take the We minutes would the through few and
population revenue; initiatives; factors: $XXX than our million revenue and the associated throughput lower revenue than with Consistent timing impacted was of DTC quarter by portfolio. second lower non-high with expected expected our three genomics of pre-announcement,
our of before genomics miss quarter, position to to none the opportunity to or technology. clear be Now our our challenge conviction competitive these But that our in market, factors. each would about the analyze like we've the had time unbounded the do, share and I I insights the to into I contributors of that QX of want broad
Addressing each turn. contributor in
population phases support First, clear early dramatically growing as programs. from can the that number It becoming vary ramp the genomics in expectations. we is a of
to in logistical several ramp more reflect timelines, more of factors, revenue due are and slower To a delaying XXXX, XXXX. our than we the In projected, number saw second forecasting. for up programs now we trajectories slowly in ramp allowing throughout quarter variable
business. in ongoing in has the Next, significant market the resulted our a in DTC array weakness shortfall
are based market forecasts, have but reflect near to on our limited in more uncertainties. the With to opportunity have unanticipated substantially DTC customer our we softness, growth, We full-year even return previously cautious expectation given lowered the when near-term of market term. will and expectations we taking the view visibility an the
impact every our And determined of four to throughput analysis miss. have to that last consumables quarter, we contributors the linked lastly, over Rather, product-specific the No customer, the negatively. routinely non-high a positively factors weeks, sequencing sometimes or theme emerged. in we single was program consistent number found miss and that sometimes no and
the In in second was quarter, not of any indicative do the net effect of business. but fundamental negative, case of we these the shifts believe the changes
assured, the prioritize looking we we're through Given the XXXX, innovation. appropriately expenses of spending always revenue rest we shortfall, carefully will operating to rest ensure are at but
we of fundamental in the exception not DTC, or genomics do any transition the with structural in opportunity. summary, the In change see
keep improving is genome. customers helping well early power role positioned a the that believe we the our are by an We of human over confident the more. that important We're play that stages will playing of thesis next in decade continue out unlock to the in to or health Illumina
but and start oncology I'm results, sequencing Sam quarter consumables by drivers. our both driving was on testing, will growth focusing for in get into going systems. This strong growth the to financial of a details
for still the are early care transform these patients. genomic is days, While oncology it information increasingly clear of standard that will
U.S., are highlighting of for a insurers lives patients covered more by in testing, and XXXX, were us. million opportunity comprehensive have or genomic XX than substantial ahead XXX their who the the of percentage In diagnosed that tumor million yet single-digit low of cancer only targeted sequenced, patients the
of around clinical targeted therapies. Researchers therapies in XXXX, therapies. it's a trials pipeline, need estimated increase there IO registered for currently XX% or evidenced IO the growing the more-personalized recognized world the and In are and we the of the global scientists saw therapies, by and that for experimental immuno-oncology in X,XXX number number over immuno
launched in XXXX, approved were with which drugs with XX were fact, diagnostics. launched predictive of nine and new for four a oncology biomarker, companion indications In
has Regulatory are help and XXX years, industry the diagnostic granted eight Designation drugs our Device novel of the closely diagnostics In including genomic bodies the introduction also on with FDA last two the working Breakthrough to companion assay assays, TSO based accelerate for content. market. the to
and Data the therapy early for recurrence continues selection emerge opportunity on ahead. highlighting to monitoring, detection, applications
With it emergence patient is will to profiling the CGP insights continued the offer of comprehensive outcomes. genomic or improve clear new that best biomarkers, genomic
as gene DNA such includes detect bio XXX, fusions. TSO year, emerging assay and this which we TSO novel markers for both known Detection is With RUO, Earlier variance, detection launched that RNA XXX TMB and of MSI. both key can Comprehensive XXX and customers our of
cancer have cause Fusions multiple types partners. tumor fusion many NTRK and across can example, For
detect with capture novel So TSO enrichment hybrid to ability method its identifying to fusion is crucial XXX's mutations. partners actionable
customers validating the offering CROs. begun including XXX, global panel the have TSO on our received have have We feedback and several of positive - become robustness
demand pleased our that performance to are has TSO expectations. share exceeded We and XXX
companies develop XXX pharma partner actionable partners indications RET will we CDx for leverage continue time, companion believe diagnostic for We with Over additional identify TSO with to to CDx TMB. and three or a to NTRK, mutations associated indications. more
for new eligibility or guideline in for recommendations, prostate stating patients' when NGS Recently, the the cancer MSI Network syndrome with updated pembrolizumab Comprehensive cancer. is method castration-resistant preferred Cancer National Lynch status prostate their testing
Additionally, development the NGS-based include MSI and notable NGS single testing could as This requirements with updated standard assay is enable and that sample. a excited of for is improving the guideline was a We're that care. germline option germline both when evidence testing XXX tissue recommended. to an TSO our is testing
to the of the operations, starting In highlighting XX NovaSeq second high in CGP, the U.S. NovaSeq quarter, that four more than Most liquid with customers. scaling oncology systems throughput. to NovaSeq associated testing customers these were realm to into firmly customers, biopsy went systems their our move went is first-time but of
NovaSeq conditions. in genomic testing. diagnose diagnostic driven to pediatric of to by is a genomic genetic estimated expensive odyssey. to added hospital testing the is the ability showing This perform are a the only with children admissions physicians testing equips condition, because that also this Genetic quarter and children's and momentum, five multi-year to It's their XX% save way up hospitals some pediatric U.S. all painful parents
Leveraging in at in the success pediatric of Hospital funding hospitals disease Florida the setting. Rady the other looking Children's Miami. for is implement genetic Hospitals genomics testing, Nicklaus clinical Notably, are to children critically-ill Children's sequencing in whole-genome
patients for genome had we million In suspected the than a of eligible have or And XXX believe for their X% sequencing yet, of patients U.S., lives disease. whole are exome covered exome sequenced. than genetic less more
Blue California year. This cover Shield from whole-genome first rapid recently of is sequencing with Street to undiagnosed Blue milestone earlier technology cover disease. major making huge Just policy sequencing Evidence California review Blue for this medical Cross the positive Shield Blue a of to health updated Shield children the whole-genome plan their following assessment
health. reproductive to Moving
largest see to expand a that combined penetration continue XX% see and or the in under high NIPT million in risk We could average risk U.S. This both around just its in of XX XX%. we China, estimate where opportunities NIPT. and the access pregnancies. benefit only to currently from births year We reach means a
we're than connection and coverage. In are NIPT of with and the had awareness revenue continued less growing record and EU, steady quarter on seeing pregnancies with improving tailwinds, adoption. XX% In reimbursement progress momentum a covered,
quarter customers the VeriSeq of last products quarter of Europe, NIPT twice reimbursement compared samples many by NIPT same driven year, in CE-IVD, growing the positive awareness and processed our to second benefits. nearly environment In the as
believe see growth of further NIPT We this are drive and will innovation excited to adoption. very level continued in for demand
the partner month, test VeriSeq resolution labs within of CE-IVD most genome, a expect products. to the VeriSeq significantly NIPT of our of be Just X vX abnormalities view interest the that type strong the comprehensive we can that across increasing expanded version CE-IVD chromosomal offers fetal NIPT, VeriSeq version to carrier other seeing detected. the which of majority is adds upgrade year. the launched a last compared to genome number and We're
projects. that genomics, have seen level other population seen have stakeholders the we commitment towards to to no shown these Turning change governments and of have
improve clinical has to the thesis genomics to initiatives population for of overall the opportunity scale care standard outcomes and medicine economic overall personalized changed. the fact, optimal the population In and patients. not offer Large ensure
They companies offer develop for genome allow discovery the benefit deepening And all. and promise to effective more accelerate they the time the human therapies market. understanding to the our from of pharma of of
to we initiatives. large therefore companies scale announcing to health It's of continue see genomics commitments a no that list countries, systems surprise pharma growing and
stakeholders, As with volume. mass critical programs complex gain can therefore, ramp many are years and and to expected, it in these take
moving large we XXXX, how these In seen initiatives timelines. have can have
genomics to most in confidence be will initiatives give programs impacted a but growth share into scale the me insight term, some driver. the Let that large have continued near us long-term that the
parties the deal continues delays all forward. involved final to the of off, in First, that was but second large alignment stakeholders. one quarter that it a associated to can with close number we the sign The between they before expected move
the in due risk Second, expectations to XX,XXX of of we program U.S. launch to linked have Us the All whole-genome timing the here decreased pilot. and some of our the full-year the
To to for be exemptions the are device samples is the investigational rather clear, the process the understand program FDA, the of process we working with of receive returning no for is funding, results approval we and shortage volunteers. to is consent IRB submitting believe to in there
resources. for are they in the counseling selecting Additionally, of providers process genetic
the a scale, we now we remain start. confident While program will XXXX project that
commissioning, system will necessary health genomic service XXX,XXX follow to in for transition. you our information U.K. the is Third, we the have undertaking implementation Incorporating decreased a a the is whole-genome midst and in of expected and building which sequencing support recall, the the full-year into testing to is the nationalized that the also clinical project expectations the small not NHS is NHS an of making adjustments routine genome
similar understanding evolve reflected Despite of able we reiterate Illumina excited human now Beyond seen is delays have we adjustments, to programs to be in are these that efforts to smaller revision. support disease. to these our and other in want that guidance timing our also health programs, these
consumer softness optimistic past long-term quarters, over genomics continued opportunity. in seen the the few are about we've DTC While we
U.S. the ever significantly in We individuals DTC test. fewer worldwide the and have estimate than that less XX% of purchased
believe world the significantly In As and is entertainment. pharmacogenomics, the we years, market see to do increase such, that we of for U.S. not and around the the in DTC expect saturated. adoption the including health applications, genealogy, wellness, level coming
allowing product offerings We new view growth of companies that this interests. meet as transitory explore which DTC a phase consumer to is evolving
committed lives. we Importantly, to believe to insights Illumina individuals DTC supporting in become customers, more empower strongly as daily our will involved is genomic their
to was human turn research. launched in now me Let XXXX. project genome The
help international Since into propel world finally health. researchers researchers, projects fund human the valuable gain XXXX. to and genome then, completed the first the With and was have insights from of continued to in sequencing around human institutions
even we're they and of research products are genetic treatment the most and impressive that cancer progress as but Alzheimer's insights our inspire stage complex in drive into to vaccines, of to their commercialized early disorders, life-saving can as We diagnose efforts touch invaluable in made disease, Parkinson's developing millions. develop treat still for scientists lives These such ability the Autism. and
to Separately, at discoveries The public scientific liquid Fred of University the Adaptive immunology went efforts. genomic Biotechnologies, years biopsy of Research will out spun And early computational resulted research, potentially month. future test. unlock Cancer who continue research Institute a new after and discovery CancerSEEK, spin-out successfully in Johns groundbreaking Hopkins Hutchinson detection last
monumental that accelerate impact software on be single-cell We're For can a sequencing discovered meaningful such excited example, microfluidics efforts. single-cell role significant ATAC-seq, have University these which a play have Harvard used new novel genomics. scientists to could see in at research to and
for dominant the technologies spend. about expected the to reinforces This Biosciences excitement as report, most SDi Global our dollar research sciences to the Assessment percentage According a instruments sequencing acquisition. Pacific of be life are
highly clinical PacBio's discoveries technology accurate for workflows technology that research with Integrating our believe sequencing short will accelerate read insights. lead we will to long help new
We year. continue with before closely of and to the the end to work regulators the close expect deal
remain of human that the in as human genomes the To the we X% a less variance mention, world understand as researchers have priorities other support are tools of date, to of function to around the to deliver to the genome, working biology innovation function remaining variance around of endeavor ascribe life. not globally Researchers understand than them. in To detected this. quality all clearly end, to our and that the basis that's industry-leading work genetic they the
Before provide about that second trends the quarter some want and I to us hand from to I the the confidence over Sam, business. overall trajectory of the key give health of
Excluding that of quarter second expectations. the expected, shipments didn't ahead large deal close as were NovaSeq
lower expect revenue We to pull and per per million XXXX Pull NovaSeq above per full-year and to over per once to up was slightly NovaSeq to in we our to system up system per year be shipments continue XXXX. compared Even grow system. through expect through to continue million flat expectations, to $X NovaSeq was be with again sequentially. $X from XXXX,
$XXX shipments time for from same a million quarter and than exceeded this SX first year the doubled the quarter more ago.
HiSeq grew and expected, both continued sequentially but combined consumables throughput to year-over-year. As high consumables decline,
We Prime shipments, than to the in S S pricing of price and of revenue SX pleased with Growth cells. and the in in the offset the impact more for SX SX flow quarter first the both response lower SX new the of while and Cell than doubled quarter, affected second decreases introduction launch. more Prime Flow are to the the
several introductions in HiSeq the trade-in throughput wave our were to ASPs part from the addition our adjustments existing of to of second conversions. program. taking quarter, and lower next customers are of catalyze NovaSeq cell NovaSeq Off NovaSeq our to in note, strategy nearly XX% multi-unit customers. And purchases NovaSeq flow advantage were pricing HiSeq purchases lower of system due
customers all quarter,\ Additionally, straight proportion desktop second orders represented from in launch. the of NovaSeq new highest to since half or over the Illumina
system We're and mid-throughput We targeted our to shipments consumables to that number growing Systems also within system we range and in see sequentially with continue were a record growth quarter report our placed of $XXX,XXX. year-over-year. placements to Dx NextSeq the NextSeq with of pleased sequencing NextSeq $XXX,XXX in associated
to and within pull was low targeted throughput and For through encouraged $XX,XXX the reflecting see range. $XX,XXX weakness pre-announce, MiniSeq slightly low year-over-year. were shipments $XX,XXX for to portfolio discussed the benchtop of our portfolio, sequentially through grew We that the MiSeq $XX,XXX, throughput pull range in was entire to both below system the
With results to quarter that, I'll review hand to Sam, over second our financial in detail. Sam?
